National Biotechnology Research Park (NBRP) was opened in Oct. 2018, and is committed to stimulate and promote valuable and effective biotechnology research in Taiwan. NBRP provides the first ecosystem platform for biomedical research on a national level. With the joint participation of industry, government, universities and national research labs, the NBRP aims to accelerate completion timelines for new drug development, with the ultimate goal of enhancing human health and welfare.

In collaboration with different ministries of Taiwan Government, BioHub Taiwan was established at NBRP. The major goal of BioHub Taiwan is to push impactful fundamental research into commercialization. Our mission is to integrate resources among the Government, Academics, and Industries to provide one stop solution. BioHub Taiwan combines Academia Sinica’s preeminent research capacities and the seven core facilities to support innovative R&D. BioHub Taiwan also integrates interdisciplinary resources into the NBRP Academy to cultivate business talents and provide business mentoring. BioHub Taiwan welcome the installation of domestic and international partners, investors and venture capitals to station at NBRP to maximize the opportunities of networking and partnering.

Innate immune molecules as promising agent for the treatment of bacterial vaginosis (BV)

Coating of antimicrobial drugs on medical devices

Drug discovery and evaluation system setup for tuberculosis (TB) infection.

Development of Anti-CD33 (S iglec-3) mAb for the Treatment of Chronic Hepatitis B Infection and Alzheimer Diseases

J4 is an ENT1 inhibitor that maintains the balance of adenosine levels inside and outside of the cell.

Development of novel hematopoietic/blood and compound therapeutics for ALS/Dementia

Synthesize various galectin inhibitors to optimize the potency and selectivity, as well as the features of blood-brain-barrier permeability and pharmacokinetics/ pharmacodynamics.

1. Cancer targeting peptides for use in the diagnosis and treatment of prostate cancer
2. Three lung cancer specific peptide ligands for targeted drug delivery, imaging and diagnosis

Using single B cell-platform to select human monoclonal antibody recognizing tumor specific glycan antigens

1. An artificial intelligence (AI) platform for designing inhibitors. 2. A smart synthesis approach to efficiently and precisely synthesize a focused library.

The glycosidic switch liposome (GSL) platform increases the power of nanomedicines by facilitating active loading, stable retention and safe delivery of drugs in liposomes.

Proprietary polymeric nanoshells for safe, precise, and multivalent T cell induction.

1. High quality proteogenomic big data and clinical data for lung and beastcancer
2. Internationally standardized platform of deep proteogenomic analysis
3. Mass spectrometry-based detection assay for cancer biomarker

1. Organic synthesis
2. Asymmetric synthesis
3. Establish the high throughput screening model systems for discovering leading drug

We developed a portable optical sensing platform with the use of capped gold nanoslits, a microfluidic device, microRNA probes and functionalized gold nanoparticles to detect specific microRNA targets in urine for early monitoring of urothelial carcinoma recurrence.

Establish a rapid screening and detection system for pesticides through high-precision enzyme display technology.

A novel method to directly reprogram human fibroblasts into retinal progenitor cells with small molecules, aiming to overcome the current bottleneck in translational medicine.

An economical and convenient body fluid target cell collect and culture platform for clinical analysis and drug test

First-in-class small-molecule drugs to reverse type two diabetes (T2D)